A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer

Capecitabine plus oxaliplatin every 3 weeks (XELOX regimen) has proven efficacy in patients with colorectal carcinoma. We investigated this combination in patients with previously untreated advanced gastric carcinoma. The study population comprised patients with histologically confirmed nonresectabl...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Y H, Kim, B-S, Ryoo, B-Y, Yang, S H
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361232/
https://www.ncbi.nlm.nih.gov/pubmed/16552439
http://dx.doi.org/10.1038/sj.bjc.6603046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361232/
https://www.ncbi.nlm.nih.gov/pubmed/16552439
http://dx.doi.org/10.1038/sj.bjc.6603046

Ejemplares similares